Global Antihelminthics Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

Recent Developments

• April 2019:The WHO prequalified VERMOX (Mebendazole) CHEWABLE, a new medicine from Janssen Pharmaceuticals Inc., for intestinal worms. Following the WHO prequalification, this product is likely to be accessible to young children under the age of one, particularly in nations with a high burden.

• September 2018:Albendazole 200 mg tablet's Abbreviated New Drug Application (ANDA) was finally approved, according to Cipla.

The global antihelminthics market can be segmented into several key categories based on the type of helminths targeted, the formulation of drugs, and the end-user applications. Primarily, the market is segmented by the type of helminths treated, including roundworms, tapeworms, flukes, and others. Each category requires specific antihelminthic treatments tailored to their lifecycle stages and infection patterns. For instance, broad-spectrum drugs may target multiple types of helminths, while narrow-spectrum drugs are designed for specific species or stages of infection.

Secondly, the market can be segmented by drug formulation, encompassing tablets, capsules, suspensions, and injectables. These formulations offer varying advantages in terms of ease of administration, patient compliance, and efficacy. Tablets and capsules are often preferred for oral administration, while injectables may be used for severe infections or veterinary applications. Additionally, the market segmentation by end-user includes human healthcare settings, veterinary clinics, and public health programs. Human healthcare settings focus on treating parasitic infections in individuals, while veterinary applications cater to animals affected by helminthiasis. Public health programs play a crucial role in mass drug administration and preventive measures in regions with high prevalence rates of helminth infections, thereby driving the demand for antihelminthic drugs globally.

Global Antihelminthics Market Analysis

The Global Antihelminthics Market has been segmented by Type, Applications, End User and Geography.

Global Antihelminthics Market, Segmentation by Type

The Global Antihelminthics Market has been segmented by Type into Hormone drugs, Abamectin, Salicylanilides, Praziquantel and Others.

The global antihelminthics market encompasses a variety of drug types designed to combat infections caused by different types of helminths. Hormone drugs, such as levamisole and niclosamide, target specific helminth species by disrupting their reproductive and metabolic processes. These drugs are effective against roundworms and tapeworms, among others, and are often used in both human and veterinary medicine. Abamectin, derived from the soil bacterium Streptomyces avermitilis, belongs to the avermectin class and is widely used in veterinary medicine to treat parasitic infections in livestock and pets. Its broad-spectrum activity against nematodes and certain ectoparasites makes it a valuable tool in animal health.

Salicylanilides, represented by drugs like closantel and rafoxanide, are effective against a range of helminths, particularly tapeworms and liver flukes. These drugs disrupt the energy metabolism and neuromuscular function of parasites, leading to their elimination from the host organism. Praziquantel is another key player in the antihelminthics market, specifically targeting tapeworms and flukes by altering their cell membrane permeability. It is highly effective and widely used in both human and veterinary medicine. Other antihelminthic drugs include benzimidazoles like albendazole and mebendazole, which are essential for treating intestinal helminth infections in humans. These drugs work by inhibiting microtubule formation in the parasite, thereby preventing its ability to absorb nutrients and reproduce.

Global Antihelminthics Market, Segmentation by Applications

The Global Antihelminthics Market has been segmented by Applications into Schistosomiasis, Fasciolasis, Filariasis, Angiostrongylosis, Ascariasis, Giardiasis and Others.

The global antihelminthics market serves a wide range of applications, each addressing specific parasitic infections prevalent in different regions worldwide. Schistosomiasis, caused by blood flukes of the genus Schistosoma, is a major focus area for antihelminthic treatment, with drugs like praziquantel being highly effective in eliminating the parasites. Fascioliasis, caused by liver flukes of the genus Fasciola, is another significant application, where drugs such as triclabendazole are used to treat both acute and chronic infections. Filariasis, a mosquito-borne parasitic disease caused by filarial worms, is targeted by drugs like diethylcarbamazine (DEC) and ivermectin, which help reduce microfilariae levels in infected individuals.

Antihelminthic drugs also play a crucial role in treating infections such as angiostrongylosis, caused by rat lungworms, and ascariasis, caused by roundworms like Ascaris lumbricoides. These infections are prevalent in tropical and subtropical regions, where access to safe water and sanitation is limited. Giardiasis, caused by the protozoan Giardia lamblia, is another key application area, with drugs like metronidazole and tinidazole used to treat intestinal infections caused by this parasite. Additionally, the market addresses other parasitic infections with specific antihelminthic therapies tailored to the lifecycle and characteristics of each pathogen. The diverse array of applications underscores the importance of antihelminthic drugs in global health efforts to combat parasitic diseases, aiming to reduce morbidity, prevent transmission, and improve overall public health outcomes.

Global Antihelminthics Market, Segmentation by End User

The Global Antihelminthics Market has been segmented by End User into Hospitals, Clinics and Others.

The global antihelminthics market caters primarily to hospitals and clinics, which are key healthcare settings where patients seek diagnosis and treatment for parasitic infections. Hospitals play a critical role in managing severe cases of helminthiasis, providing advanced diagnostic facilities and access to specialized antihelminthic therapies. Clinics, including both general practice clinics and specialized parasitology clinics, serve as primary points of care where patients receive initial diagnosis, treatment, and follow-up care for various parasitic infections. These settings often administer outpatient treatments and monitor patient progress to ensure effective management of helminthiasis.

Beyond hospitals and clinics, the antihelminthics market also encompasses other end users such as public health programs, community health centers, and veterinary clinics. Public health programs are instrumental in mass drug administration campaigns aimed at controlling and eliminating parasitic infections in endemic regions. They facilitate distribution of antihelminthic drugs to at-risk populations, implement preventive measures, and conduct epidemiological surveillance to monitor disease prevalence. Veterinary clinics utilize antihelminthic drugs for the treatment and prevention of parasitic infections in livestock, pets, and other animals, contributing to animal health and welfare globally. Together, these diverse end users highlight the broad impact of antihelminthic therapies across human and veterinary healthcare sectors in addressing the global burden of parasitic diseases.

Global Antihelminthics Market, Segmentation by Geography

The Global Antihelminthics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Antihelminthics Market Share (%), by Geographical Region, 2023

The global antihelminthics market is segmented into five key regions: North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America and Europe dominate the market due to high healthcare spending, advanced medical infrastructure, and a significant burden of parasitic infections necessitating antihelminthic treatments. The presence of major pharmaceutical companies focusing on research and development further enhances market growth in these regions. Moreover, stringent regulatory frameworks ensure high standards of drug efficacy and safety, contributing to market expansion.

Asia Pacific is poised for substantial growth in the antihelminthics market, driven by large patient populations affected by parasitic diseases and increasing awareness about treatment options. The region's economic development is also boosting healthcare access, particularly in rural areas where parasitic infections are prevalent. In contrast, the Middle East and Africa face challenges such as limited access to healthcare facilities and resources, hindering market growth despite a high prevalence of parasitic diseases. Latin America exhibits moderate growth potential, driven by improving healthcare infrastructure and rising healthcare expenditure aimed at combating parasitic infections effectively. Overall, the global antihelminthics market is characterized by regional variations in disease burden, healthcare access, and regulatory environments influencing market dynamics across these diverse regions.

This report provides an in depth analysis of various factors that impact the dynamics of Global Antihelminthics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers:

• Expansion of Healthcare Access in Developing Regions
• Rising Demand for Veterinary Antiparasitic Treatments
• Government Support and Funding for Control Programs

• Growing Awareness about Neglected Tropical Diseases: The global antihelminthics market is witnessing a surge in awareness about neglected tropical diseases (NTDs), driving significant growth. These diseases, predominantly affecting populations in low-income regions of Asia, Africa, and Latin America, are characterized by high morbidity and mortality rates. Increasing efforts by governments, non-governmental organizations (NGOs), and international health bodies to raise awareness about NTDs such as soil-transmitted helminthiasis, schistosomiasis, and lymphatic filariasis have propelled the demand for antihelminthic treatments. The emphasis on preventive chemotherapy programs and mass drug administration campaigns has further bolstered market growth, aiming to reduce the burden of these diseases on vulnerable populations.

  Pharmaceutical companies are increasingly focusing on developing affordable and accessible antihelminthic drugs tailored to the specific needs of endemic regions. Collaborations between governments, NGOs, and healthcare providers are crucial in expanding treatment coverage and ensuring sustainability in disease control efforts. As awareness continues to grow, particularly through educational initiatives and community engagement, the global antihelminthics market is poised to see continued expansion in addressing neglected tropical diseases effectively.

Restraints:

• Drug Resistance in Helminths
• Limited Access to Healthcare in Remote Areas
• High Cost of Antihelminthic Treatments

• Adverse Effects and Safety Concerns: The global antihelminthics market faces challenges related to adverse effects and safety concerns, which impact its growth and adoption. Many antihelminthic drugs, while effective in treating parasitic infections, can cause a range of adverse effects such as nausea, vomiting, abdominal pain, and dizziness. These side effects can lead to patient non-compliance or discontinuation of treatment, particularly in vulnerable populations such as children and pregnant women. Moreover, certain antihelminthic medications have been associated with more serious adverse reactions, including liver toxicity and neurological symptoms, which underscore the importance of careful monitoring and dosage management.

  Safety concerns also extend to drug resistance, where repeated or improper use of antihelminthics can lead to the development of resistant parasites. This poses a significant challenge in regions with endemic parasitic diseases, necessitating ongoing research and development of new treatment options. Regulatory bodies play a crucial role in ensuring the safety and efficacy of antihelminthics through rigorous approval processes and post-market surveillance, aiming to mitigate risks while promoting effective treatment outcomes. Addressing these adverse effects and safety concerns remains pivotal for sustaining growth and enhancing the global antihelminthics market's role in combating parasitic infections worldwide.

Opportunities:

• Development of Novel Antihelminthic Formulations
• Expansion of Screening and Treatment Programs
• Increasing Focus on One Health Approach

• Collaboration for Research and Development: Collaboration for research and development is increasingly vital in the global antihelminthics market to address the complex challenges posed by parasitic infections. Pharmaceutical companies, academic institutions, governments, and non-profit organizations are pooling resources and expertise to accelerate the discovery and development of new antihelminthic treatments. These collaborations leverage diverse perspectives and capabilities to innovate in drug discovery, formulation, and delivery systems tailored to specific parasitic diseases prevalent in different regions.

  Partnerships facilitate the sharing of scientific knowledge, data, and clinical trial resources, expediting the evaluation of potential antihelminthic candidates. Initiatives like public-private partnerships and consortia dedicated to neglected tropical diseases ensure that research efforts are focused on the most pressing global health priorities. By fostering collaboration across borders and disciplines, the global antihelminthics market can effectively tackle emerging challenges such as drug resistance and safety concerns while striving to provide affordable and accessible treatments to underserved populations.